FI113542B - Steroideja, jotka sisältävät 17-spirometyleenilaktoniryhmän - Google Patents

Steroideja, jotka sisältävät 17-spirometyleenilaktoniryhmän Download PDF

Info

Publication number
FI113542B
FI113542B FI955108A FI955108A FI113542B FI 113542 B FI113542 B FI 113542B FI 955108 A FI955108 A FI 955108A FI 955108 A FI955108 A FI 955108A FI 113542 B FI113542 B FI 113542B
Authority
FI
Finland
Prior art keywords
hydroxy
lactone
diene
norcola
solution
Prior art date
Application number
FI955108A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI955108A0 (fi
FI955108A (fi
Inventor
Johannes Antonius Mar Hamersma
Der Louw Jaap Van
Original Assignee
Akzo Nobel Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel Nv filed Critical Akzo Nobel Nv
Publication of FI955108A0 publication Critical patent/FI955108A0/fi
Publication of FI955108A publication Critical patent/FI955108A/fi
Application granted granted Critical
Publication of FI113542B publication Critical patent/FI113542B/fi

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J19/00Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 by a lactone ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J21/00Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J21/005Ketals
    • C07J21/006Ketals at position 3
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18Feminine contraceptives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J1/00Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051Estrane derivatives
    • C07J1/0081Substituted in position 17 alfa and 17 beta
    • C07J1/0088Substituted in position 17 alfa and 17 beta the substituent in position 17 alfa being an unsaturated hydrocarbon group
    • C07J1/0092Alkenyl derivatives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J17/00Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J21/00Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J21/001Lactones
    • C07J21/003Lactones at position 17
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J31/00Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J41/00Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • C07J41/0016Oximes
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J51/00Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J9/00Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J9/00Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gynecology & Obstetrics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FI955108A 1994-10-27 1995-10-26 Steroideja, jotka sisältävät 17-spirometyleenilaktoniryhmän FI113542B (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP94203117 1994-10-27
EP94203117 1994-10-27

Publications (3)

Publication Number Publication Date
FI955108A0 FI955108A0 (fi) 1995-10-26
FI955108A FI955108A (fi) 1996-04-28
FI113542B true FI113542B (fi) 2004-05-14

Family

ID=8217314

Family Applications (1)

Application Number Title Priority Date Filing Date
FI955108A FI113542B (fi) 1994-10-27 1995-10-26 Steroideja, jotka sisältävät 17-spirometyleenilaktoniryhmän

Country Status (26)

Country Link
US (1) US5741786A (no)
EP (1) EP0709394B1 (no)
JP (1) JPH08225590A (no)
KR (1) KR100402636B1 (no)
CN (1) CN1052237C (no)
AT (1) ATE199015T1 (no)
AU (1) AU689642B2 (no)
BR (1) BR9504576A (no)
CA (1) CA2161490A1 (no)
CZ (1) CZ287346B6 (no)
DE (1) DE69520022T2 (no)
DK (1) DK0709394T3 (no)
ES (1) ES2157290T3 (no)
FI (1) FI113542B (no)
GR (1) GR3035713T3 (no)
HU (1) HU221192B1 (no)
IL (1) IL115659A (no)
NO (1) NO305252B1 (no)
NZ (1) NZ280325A (no)
PL (1) PL187083B1 (no)
PT (1) PT709394E (no)
RU (1) RU2168516C2 (no)
SG (1) SG33569A1 (no)
TR (1) TR199501327A2 (no)
TW (1) TW339337B (no)
ZA (1) ZA958963B (no)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6407082B1 (en) * 1996-09-13 2002-06-18 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of a vitamin D compound
US6511970B1 (en) 1996-09-13 2003-01-28 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of products that induce transforming growth factor-beta and/or apoptosis in the ovarian epithelium
US6028064A (en) 1996-09-13 2000-02-22 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of progestin products
US6765002B2 (en) 2000-03-21 2004-07-20 Gustavo Rodriguez Prevention of ovarian cancer by administration of products that induce transforming growth factor-β and/or apoptosis in the ovarian epithelium
US6034074A (en) 1996-09-13 2000-03-07 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of a Vitamin D compound
DE19651000A1 (de) * 1996-12-01 1998-06-04 Schering Ag Oxyiminopregnancarbolactone
ATE473759T1 (de) 1998-05-22 2010-07-15 Univ Leland Stanford Junior Bifunktionelle moleküle sowie darauf basierende therapien.
US6043235A (en) * 1999-07-21 2000-03-28 Research Triangle Institute 11β-aryl-17, 17-spirothiolane-substituted steroids
US20010044431A1 (en) * 2000-03-21 2001-11-22 Rodriguez Gustavo C. Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium
DE60234057D1 (de) 2001-07-25 2009-11-26 Raptor Pharmaceutical Inc Zusammensetzungen und verfahren zur modulation des transports durch die blut-hirn-schranke
EP2392258B1 (en) 2005-04-28 2014-10-08 Proteus Digital Health, Inc. Pharma-informatics system
US9062126B2 (en) 2005-09-16 2015-06-23 Raptor Pharmaceuticals Inc. Compositions comprising receptor-associated protein (RAP) variants specific for CR-containing proteins and uses thereof
AU2010216512B2 (en) 2009-02-20 2016-06-30 2-Bbb Medicines B.V. Glutathione-based drug delivery system
WO2010129819A2 (en) 2009-05-06 2010-11-11 Laboratory Skin Care, Inc. Dermal delivery compositions comprising active agent-calcium phosphate particle complexes and methods of using the same
EP4127341A1 (en) * 2020-04-03 2023-02-08 Rockwool A/S Method of draining water

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2875199A (en) * 1958-04-22 1959-02-24 Searle & Co Lactones of 17-carboxyalkylated estra-1, 3, 5(10)-triene-3, 17-diols and 3-ethers
US3547912A (en) * 1968-07-29 1970-12-15 American Home Prod Derivatives of 2h-pyran-3(6h)-ones and preparation thereof
US3764596A (en) * 1971-06-22 1973-10-09 Sandoz Ag 17-dihydrofuranyl-substituted steroids
DE3878198T2 (de) * 1987-12-12 1993-06-24 Akzo Nv 11-arylsteroid-derivate.
FR2688004A1 (fr) * 1992-02-27 1993-09-03 Roussel Uclaf Nouveaux sterouides comportant en position 17 un radical methylene lactone, leur procede et des intermediaires de preparation, leur application comme medicaments.

Also Published As

Publication number Publication date
NO954293L (no) 1996-04-29
KR960014152A (ko) 1996-05-22
CZ275595A3 (en) 1996-05-15
NZ280325A (en) 1997-03-24
HU221192B1 (en) 2002-08-28
CZ287346B6 (en) 2000-10-11
US5741786A (en) 1998-04-21
CN1131158A (zh) 1996-09-18
EP0709394B1 (en) 2001-01-31
DK0709394T3 (da) 2001-06-18
SG33569A1 (en) 1996-10-18
IL115659A (en) 2000-06-01
CA2161490A1 (en) 1996-04-28
EP0709394A3 (en) 1996-09-18
PT709394E (pt) 2001-06-29
ZA958963B (en) 1996-05-23
FI955108A0 (fi) 1995-10-26
PL311135A1 (en) 1996-04-29
EP0709394A2 (en) 1996-05-01
ATE199015T1 (de) 2001-02-15
AU3445795A (en) 1996-05-09
CN1052237C (zh) 2000-05-10
PL187083B1 (pl) 2004-05-31
NO954293D0 (no) 1995-10-26
HUT73482A (en) 1996-08-28
TR199501327A2 (tr) 1996-06-21
DE69520022D1 (de) 2001-03-08
JPH08225590A (ja) 1996-09-03
TW339337B (en) 1998-09-01
KR100402636B1 (ko) 2004-02-05
NO305252B1 (no) 1999-04-26
RU2168516C2 (ru) 2001-06-10
HU9503068D0 (en) 1995-12-28
IL115659A0 (en) 1996-01-19
GR3035713T3 (en) 2001-07-31
AU689642B2 (en) 1998-04-02
ES2157290T3 (es) 2001-08-16
DE69520022T2 (de) 2001-06-13
TR199501327A3 (no) 1996-06-21
BR9504576A (pt) 1997-05-20
FI955108A (fi) 1996-04-28

Similar Documents

Publication Publication Date Title
FI113542B (fi) Steroideja, jotka sisältävät 17-spirometyleenilaktoniryhmän
US5292878A (en) 17-spirofuran-3'-ylidene steroids
AU778017B2 (en) 14,15-beta-methylene substituted androgens
KR100341066B1 (ko) 게스타겐활성의19,11-다리결합4-에스트렌
EP1163259B1 (en) 14.beta.,17-alpha-hydroxymethylandrostane derivatives as androgens
KR100400621B1 (ko) 14알파,17알파-c2-브리지된19-노르-프로게스테론유도체
KR100730010B1 (ko) 신규 안드로겐
WO1995011915A1 (de) 10,11β-C2-ÜBERBRÜCKTE STEROIDE

Legal Events

Date Code Title Description
MA Patent expired